Empowering investors with access to the best research, experts and opportunities.
7th March 2026
7th May 2026
16th May 2024
Live Investor Briefing
In this session Felix Gold Executive Director Joseph Webb discussed their plans to develop a potential multi million ounce high grade gold resource.
Speaker
DR Gerard Dyson Managing Director – Spectur Limited (ASX: SP3)
18th April 2024
In this session Far East Gold’s CEO and Director Shane Menere discussed the standout assays from our Woyla drilling campaigns that form the base of our upcoming maiden JORC resource publication.
9th April 2024
In this session Prescient CEO and Managing Director Steven Yatomi-Clarke discussed why the data from their PTX-100 Phase 1b trial is so promising.
25th March 2024
In this session Prescient CEO and Managing Director Steven Yatomi-Clarke provide a company update on strategy and upcoming milestones.
DR Gerard Dyson
Managing Director – Spectur Limited (ASX: SP3)
14th March 2024
Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.
22nd February 2024
In this session Far East Gold’s CEO and Director Shane Menere discussed, why the Board (including Nickel Industries MD Justin Werner) is optimistic about the findings so far……
15th February 2024
In this session Wellnex Life MD Zack Bozinovski and Non-Executive Chairman Mario Tascone discussed what attracted Mario to Wellnex and where he sees the future of the business;
17th November 2020
Marenica Energy (ASX: MEY) Managing Director Murray Hill provides an outline of their massive 94 million pound uranium asset as well as an overview of their patented U-pgrade process developed alongside the CSIRO that can reduce uranium production cost by 50%.
16th November 2020
This week we were joined by the CEOs of exciting ASX listed businesses, who gave valuable insight to their industries and companies future prospects. TZ Limited (ASX: TZL), Antisense Therapeutics (ASX: ANP) and Change Financial (ASX: CCA).
Martin Filz, CEO at Pureprofile (ASX: PPL) discusses how Pureprofile are positioned to be big winners from massive growth of the digital economy and changes triggered by global data privacy crackdowns.
13th November 2020
12th November 2020
Prescient Therapeutics (ASX: PTX) Webcast Replay Steven Yatomi-Clarke, CEO & MD of Prescient Therapeutics (ASX:PTX) provides an update on the company’s promising pipeline of cancer treatments, cell therapy enhancements and next-gen CAR-T 'OmniCAR', which inserts PTX into the forefront of...
11th November 2020
6th November 2020
Martin Filz, CEO at Pureprofile (ASX: PPL) discusses how Pureprofile are potentially big winners from massive growth of the digital economy and changes triggered by global data privacy crackdowns.
4th November 2020
This week we were joined by the CEOs of exciting ASX listed businesses, who gave valuable insight to their industries and companies future prospects.
Prescient Therapeutics (ASX:PTX) are focused on developing novel, personalised therapies for a range of cancers through universal CAR-T and targeted therapies.
Pureprofile (ASX: PPL) connects businesses with empowered consumers across the world by connecting, understanding and engaging them through direct-to-consumer technology platforms.
By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.